Skip to main content

Alogliptin / Pioglitazone Dosage

Medically reviewed by Drugs.com. Last updated on Aug 16, 2023.

Applies to the following strengths: 12.5 mg-15 mg; 12.5 mg-30 mg; 12.5 mg-45 mg; 25 mg-15 mg; 25 mg-30 mg; 25 mg-45 mg

Usual Adult Dose for Diabetes Type 2

Individualize dose based on current regimen and concurrent medical condition:

For patients inadequately controlled on diet and exercise or metformin monotherapy:

For patients on pioglitazone requiring additional glycemic control:
For patients with congestive heart failure (NYHA Class I or II):
For patients switching from individual components:

Titrate dose based on glycemic response as determined by hemoglobin A1c (HbA1c).
Maximum dose: Alogliptin 25 mg per day; Pioglitazone 45 mg per day.

Comments: When used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be required to minimize the risk of hypoglycemia.

Use: As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetess when treatment with both alogliptin and pioglitazone is appropriate.

Renal Dose Adjustments

Mild renal dysfunction (CrCl greater than or equal to 60 mL/min): No adjustment recommended.
Moderate renal dysfunction (CrCl 30 mL/min to less than 60 mL/min): alogliptin-pioglitazone 12.5 mg/15 mg, 12.5 mg/30 mg, or 12.5 mg/45 mg orally once a day
Severe renal dysfunction or ESRD: Not recommended.

For patients with severe renal impairment: coadministration of alogliptin 6.25 mg orally once a day with pioglitazone orally once a day may be considered, however, this dose is not available in a combination tablet.

Liver Dose Adjustments

Use caution:

Dose Adjustments

For patients with congestive heart failure (NYHA Class I or II):


Coadministration with Strong CYP450 2C8 Inhibitors:

Due to risk of hypoglycemia if used in combination with sulfonylurea, or insulin, a lower dose of the sulfonylurea or insulin should be considered.

Precautions

US BOXED WARNING: CONGESTIVE HEART FAILURE:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for dosing related precautions

Dialysis

Data not available

Other Comments

Administration advice:


General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.